Management of Ureaplasma Infections

First‑Line Treatment

The CDC recommends a single oral dose of azithromycin 1 g for confirmed Ureaplasma infection in adults, providing superior compliance through directly observed therapy. 1, 2, 3, 4
Azithromycin 1 g given on‑site (e.g., in the clinic) should be used whenever possible to ensure directly observed administration and to maximize adherence, especially in populations unlikely to return for follow‑up. 1, 3
Patients should abstain from sexual intercourse for 7 days after starting azithromycin to prevent onward transmission, even if symptoms resolve earlier. 3

Doxycycline 100 mg orally twice daily for 7 days is an equally effective alternative to azithromycin for Ureaplasma infection. 1, 2, 3, 4
Although doxycycline is less expensive and has a longer history of use, the 7‑day course poses greater adherence challenges compared with a single‑dose azithromycin regimen. 2

For persistent urethritis after initial therapy, repeat the original regimen only when the patient was non‑compliant or has been re‑exposed to an untreated partner. 1, 3, 4
When compliance is confirmed and re‑exposure is excluded, consider the possibility of tetracycline‑resistant U. urealyticum as a cause of recurrence after doxycycline. 1, 4
An alternative regimen for documented persistent infection is metronidazole 2 g single dose plus erythromycin base 500 mg four times daily for 7 days. 1, 4

Ofloxacin 300 mg orally twice daily for 7 days is recommended for patients who cannot receive macrolides. 1, 2, 3, 4
Levofloxacin 500 mg orally once daily for 7 days is an additional fluoroquinolone option. 1, 3, 4
Fluoroquinolones must not be used in pregnancy or in individuals younger than 18 years because of potential cartilage toxicity. 2

All sexual partners within the preceding 60 days should be evaluated and treated with the same regimen as the index patient, regardless of symptoms or test results. 1, 3, 4
Treating partners is essential to prevent reinfection of the index case and further transmission. 2

Testing for Chlamydia trachomatis and Neisseria gonorrhoeae is strongly recommended because these pathogens frequently co‑exist with Ureaplasma. 1, 2, 3

Do not retreat based solely on symptoms; retreatment requires objective laboratory evidence of persistent urethritis (e.g., >5 WBCs per oil‑immersion field on urethral Gram stain or >10 WBCs per high‑power field on first‑void urine). 1, 3, 4
Do not omit testing for C. trachomatis, which co‑exists in approximately 16‑24 % of Ureaplasma cases and requires the same antimicrobial regimen. 1, 2, 3

The Centers for Disease Control and Prevention recommends azithromycin 1g orally in a single dose as the standard first-line treatment for Ureaplasma urealyticum infections 5, 6, 7
The European Association of Urology suggests doxycycline 100mg orally twice daily for 7 days as an alternative first-line option 5, 6, 7

For persistent or chronic infections, the European Urology guidelines recommend considering azithromycin 500mg on day 1, followed by 250mg daily for 4 additional days 7

The Centers for Disease Control and Prevention recommends re-treating with the initial regimen if compliance was poor, or considering alternative regimens such as metronidazole 2g orally in a single dose PLUS erythromycin base 500mg orally four times daily for 7 days 5
The European Association of Urology suggests moxifloxacin 400mg daily for 7-14 days if macrolide resistance is suspected 7

The Centers for Disease Control and Prevention recommends that all sexual partners within the preceding 60 days should be referred for evaluation and treatment, and receive the same treatment regimen as the index case 5, 8
Patients should abstain from sexual intercourse until therapy is completed and symptoms have resolved 5, 8

The Centers for Disease Control and Prevention warns against failing to test for other co-infections like Chlamydia trachomatis, which frequently co-exists with Ureaplasma 5, 8
The European Association of Urology guidelines advise against retreating based on symptoms alone without laboratory confirmation of persistent infection, and emphasize the importance of addressing sexual partners to prevent reinfection 5, 8